



**FOR IMMEDIATE RELEASE
NEWS RELEASE**

TSX Venture: AMF

**AMORFIX AND THE ONTARIO GENOMICS INSTITUTE
ANNOUNCE PARTNERSHIP TO ACCELERATE DEVELOPMENT OF
A BLOOD TEST FOR ALZHEIMER'S DISEASE**

TORONTO, ON, January 31, 2006 – Amorfix Life Sciences Inc. and the Ontario Genomics Institute (OGI) announced today they are entering into a partnership to develop a blood test for Alzheimer's disease, EP-AD™, based upon Amorfix's patent-pending Epitope Protection technology. OGI will assist Amorfix in accelerating its program for diagnosis of neurodegenerative diseases drawing on OGI's portfolio of state-of-the-art genomics and proteomics facilities, research and pre-commercial development in Ontario.

Dr. George Adams, Amorfix's CEO said, "Alzheimer's Disease affects 10% of people over 65 years old and there is no definitive way to confirm a diagnosis before death. I am very pleased to have OGI's support as we aim to be the first to develop a definitive blood test for Alzheimer's".

Alzheimer's disease is associated with an accumulation of protein aggregates, called amyloid, in the brain. Recent research has suggested that these amyloid aggregates result from aggregation of misfolded A-beta protein fragments. A-beta is present in blood and the company believes aggregates are also present in the circulation in Alzheimer's patients. Dr. Neil Cashman, Amorfix's CSO said, "Until now, it has been very difficult to detect aggregated misfolded proteins in blood where normal protein is prevalent. With our progress on the Epitope Protection platform, we are now in a position to finish our development of a test for Alzheimer's A-beta aggregates in blood."

"We are very excited to partner with Amorfix to expedite the translation of leading research discoveries for public benefit", said Dr. Christian Burks, OGI President and CEO. "Ontario, with its leading-edge genomics and proteomics research community, is uniquely positioned to foster advances in our understanding of the role of protein misfolding and aggregation in human disease, and Amorfix is uniquely positioned to apply this understanding to discovery of better diagnostics tools and therapies for Alzheimer's and other neurodegenerative diseases."

Pursuant to a term sheet executed December 22, 2005, OGI has executed a subscription agreement to invest \$100,000 in Amorfix to accelerate the EP-AD™ project. OGI will, upon closing, invest \$50,000 receiving 100,000 common shares of AMF and 50,000 warrants to purchase shares for \$.90 for a term of two years. Upon the achievement of a defined research milestone, OGI will invest \$50,000 at market price and receive a one-half warrant for each share purchased to purchase a share at the then market price within 2 years. This transaction is subject to acceptance for filing by the TSX Venture exchange.

About OGI

The Ontario Genomics Institute is a private, not-for-profit corporation focused on building a globally-competitive life sciences industry in Ontario. Through its relationship with Genome Canada, the Ontario Ministry of Economic Development and Trade (MEDT), the newly created Ontario Ministry of Research and Innovation (MRI) and other private and public sector partners, OGI helps Ontario-based scientists secure funding for genomics-driven research and commercialization.

For further information, visit www.OntarioGenomics.ca or contact:

Hélène Laurin, Director of Communications
Ontario Genomics Institute
416-977-9582 ext.284
hlaurin@ontariogenomics.ca

About Amorfix

Amorfix is an emerging theranostics company focused on the diagnosis and treatment of neurodegenerative diseases, where aggregated misfolded proteins (AMPs) are prevalent. These include aggregated misfolded prion protein which makes up “prions,” the infectious agents of the Transmissible Spongiform Encephalopathies (TSE), such as Bovine Spongiform Encephalopathy (BSE or "mad cow disease") and the human form, variant Creutzfeldt-Jakob Disease (vCJD), as well as degenerative diseases such as Alzheimer’s Disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s Disease (PD). Amorfix was formed to commercialize epitope protection (EP) technologies and related discoveries to become the world leader on AMP diseases. The company will use this new knowledge to develop diagnostic kits, therapeutics and prophylactics for AMP diseases.

For further information, visit the website at www.amorfix.com or contact:

Dr. George Adams, President and CEO
Amorfix Life Sciences Ltd.
416-557-4647
george.adams@amorfix.com

James Parsons, CFO
Amorfix Life Sciences Ltd.
416-705-5686
james.parsons@amorfix.com

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Actual future results may differ materially from those contemplated. The risks, uncertainties and other factors that could influence the actual results are described in documents filed with regulatory authorities.